The mechanistic role of tirzepatide in atherosclerosis: A review.
Al-Kuraishy. Hayder M HM; Sulaiman. Ghassan M GM; Mohammed. Hamdoon A HA; Saad. Hebatallah M HM; Waheed. Huda J HJ; Jabir. Majid S MS; Al-Gareeb. Ali I AI; Albuhadily. Ali K AK
Key Findings
- Tirzepatide is approved for obesity and type‑2 diabetes management
- Obesity, diabetes and inflammation are major drivers of atherosclerosis
- Animal and early human data suggest tirzepatide reduces arterial inflammation, though the precise pathways are still being studied
Practical Outcomes
- For biohackers, tirzepatide may offer added heart‑health benefits beyond weight loss, but there’s no specific dosing or protocol yet. It’s worth watching as more clinical data emerge, and any use should be under medical supervision.
Summary
This review says tirzepatide, a drug already used for weight loss and type‑2 diabetes, also appears to calm the inflammation that drives artery plaque buildup, but scientists still aren’t sure exactly how it works.
Abstract
Atherosclerosis is the leading cause of death worldwide, characterized by progressive deposition of lipids, fibrous elements, and calcification in the large arteries. The pathophysiology of atherosclerosis is complex and related to diverse mechanisms. Prominently, obesity, type 2 diabetes (T2D), and associated inflammation are common modifiable risk factors implicated in the pathogenesis of atherosclerosis. Henceforth, targeting of obesity, T2D, and linked inflammation may reduce risk for the development and progression of atherosclerosis. Researchers have demonstrated that tirzepatide, a recently approved drug for managing obesity and T2D, can reduce inflammatory changes in atherosclerosis. Nevertheless, the fundamental mechanism of tirzepatide against atherosclerosis is not completely clarified. Consequently, this review aims to discuss the mechanism of tirzepatide against atherosclerosis.
Study Information
pubmed
2025
2025-09-17T00:00:00.000Z
10.1016/j.ijbiomac.2025.147734
105